Jens Eckstein

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.

GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California.

Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.

Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.

Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands.

Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.

HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation.